Adagene Unveils Promising Clinical Data at ESMO Congress
At the recent ESMO Congress, Adagene Inc. presented exciting clinical findings regarding its experimental treatment, ADG126, aimed at patients dealing with advanced colorectal cancer. This development indicates that combining ADG126 with KEYTRUDA (pembrolizumab) could bring a new sense of hope for individuals battling advanced or metastatic microsatellite-stable (MSS) colorectal cancer (CRC), which often has limited treatment options available.
Key Clinical Outcomes Highlighted
During the congress, it was shared that the confirmed partial responses (PRs) in patients receiving ADG126 have significantly increased, reaching four responses in total. The study focused on MSS CRC patients who did not have liver or peritoneal metastases, showing an overall response rate (ORR) of 24% with a dosing regimen of 10 mg/kg every three weeks.
Survival Rates and Progression-Free Survival
Alongside the encouraging response data, the effectiveness of the treatment is underscored by a median progression-free survival (PFS) of 8.5 months in the same patient group at the 10 mg/kg dosage. The study also revealed strong 12-month overall survival (OS) rates, with 74% for patients without liver metastases and 82% for those with neither liver nor peritoneal metastases.
Insights on Safety Profile
The safety profile of ADG126 is looking positive, reporting a 16% occurrence of Grade 3 treatment-related adverse events (TRAEs) among individuals receiving the combination therapy. This suggests that ADG126 has the potential to be used alongside standard care treatments, providing hope for a broader range of patients, including those with liver metastases.
Meeting Patient Needs Effectively
Dr. Daneng Li, a leading investigator in the study, noted that the efficacy results are particularly promising given the low toxicity associated with ADG126. With a significantly higher dosing level compared to existing anti-CTLA-4 therapies, it becomes increasingly evident that ADG126 could be a viable option for many patients in need of advanced treatment.
The Mechanism of Action and Distinctiveness of ADG126
ADG126 functions as a masked anti-CTLA-4 SAFEbody, specifically targeting an epitope on regulatory T cells present in tumor tissues. The innovative design of this therapy allows for targeted action against tumors while reducing the adverse effects commonly experienced with traditional therapeutic antibodies. This targeted approach is achieved without significant levels of immunogenicity or the formation of anti-drug antibodies, marking a considerable advantage as the field moves forward.
Looking Ahead: Future Directions for ADG126
The data shared at the congress showcases a strong commitment to patient safety and provides insight into ADG126's potential to produce meaningful clinical responses. Peter Luo, CEO of Adagene, suggested that ongoing studies will explore the use of ADG126 at much higher doses than those of conventional treatments. This ambitious plan could pave the way for patients to access groundbreaking therapies that aim for significant improvements in overall outcomes.
Frequently Asked Questions
What is ADG126?
ADG126 is a masked anti-CTLA-4 SAFEbody developed by Adagene to improve safety and effectiveness when combined with pembrolizumab for colorectal cancer treatment.
What key findings emerged from the ESMO Congress?
Key findings included a 24% overall response rate and a median progression-free survival of 8.5 months in patients treated with ADG126 alongside pembrolizumab.
How safe is the combination therapy of ADG126 with KEYTRUDA?
This combination therapy exhibited only a 16% occurrence of Grade 3 treatment-related adverse events, indicating a promising safety profile.
Who could benefit from ADG126?
Patients grappling with advanced or metastatic MSS colorectal cancer, particularly those with liver metastases, stand to gain the most from ADG126 treatment, which provides an option in a limited landscape.
What does the future look like for ADG126?
Adagene intends to investigate higher dosing regimens of ADG126 in clinical trials, aiming to enhance its efficacy and potentially improve patient outcomes across a broader patient population.
